Arbutus Biopharma Corporation - Common Stock - balanço patrimonial (NASDAQ:ABUS)

Financials

Total de ativos 137.08 M204.49 M195.42 M144.4 M131.71 M94.62 M Total de passivos 35.11 M35.05 M58.57 M38.38 M34.34 M18.04 M Capital total 101.97 M169.44 M136.85 M106.02 M97.37 M76.58 M Total de passivos e patrimônio líquido 137.08 M204.49 M195.42 M144.4 M131.71 M94.62 M Dívida total —————— Dívida líquida ——————

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

ABUS

Financials

Arbutus Biopharma Corporation - Common Stock

Notícias

Lucro da Arbutus Biopharma superou projeções por $0,91; receita supera estimativas

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS)

Moderna's Revenues See Strong International Momentum in Q1 Earnings

Moderna's Quarterly Earnings Preview: What You Need to Know

Lucro da Arbutus Biopharma superou projeções por $0,02; receita supera estimativas

Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation

Why Moderna’s $950M Patent Bill Is A Small Price For Pipeline Freedom (NASDAQ:MRNA)

Chardan reitera recomendação de compra para Arbutus Biopharma após acordo com Moderna

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Ações da Moderna atingem máxima de 52 semanas a US$ 55,22

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang